Geron Corp. (NASDAQ:GERN) shares were down 2.2% on Tuesday . The stock traded as low as $2.69 and last traded at $2.69, with a volume of 817,574 shares traded. The stock had previously closed at $2.75.

Several research analysts recently weighed in on GERN shares. FBR & Co reiterated a “buy” rating on shares of Geron Corp. in a research report on Sunday, May 8th. Zacks Investment Research lowered Geron Corp. from a “hold” rating to a “sell” rating in a research report on Tuesday, May 10th. Two analysts have rated the stock with a sell rating and five have issued a buy rating to the stock. Geron Corp. presently has an average rating of “Hold” and an average price target of $6.13.

The company has a 50-day moving average of $2.78 and a 200-day moving average of $3.00. The stock has a market capitalization of $429.19 million and a price-to-earnings ratio of 900.00.

Geron Corp. (NASDAQ:GERN) last issued its quarterly earnings results on Thursday, May 5th. The biopharmaceutical company reported ($0.06) EPS for the quarter, hitting the consensus estimate of ($0.06). During the same period in the previous year, the business posted ($0.06) EPS. The company had revenue of $0.74 million for the quarter, compared to the consensus estimate of $0.26 million. The business’s revenue for the quarter was up 37.0% on a year-over-year basis. Equities research analysts predict that Geron Corp. will post ($0.26) EPS for the current year.

Other institutional investors recently modified their holdings of the company. American Century Companies Inc. boosted its position in shares of Geron Corp. by 22.6% in the fourth quarter. American Century Companies Inc. now owns 687,621 shares of the biopharmaceutical company’s stock valued at $3,328,000 after buying an additional 126,770 shares during the last quarter. California State Teachers Retirement System boosted its position in shares of Geron Corp. by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 292,950 shares of the biopharmaceutical company’s stock valued at $1,418,000 after buying an additional 5,223 shares during the last quarter. EAM Investors LLC bought a new position in shares of Geron Corp. during the fourth quarter valued at approximately $1,317,000. Morgan Stanley boosted its position in shares of Geron Corp. by 194.2% in the fourth quarter. Morgan Stanley now owns 268,626 shares of the biopharmaceutical company’s stock valued at $1,300,000 after buying an additional 177,313 shares during the last quarter. Finally, Russell Frank Co bought a new position in shares of Geron Corp. during the fourth quarter valued at approximately $1,099,000.

Geron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc (Janssen). The Company operates through the segment, which includes discovery and development of therapeutic products for oncology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.